儿童炎症性肠病生物制剂暴露的不可阻挡增长:一项苏格兰人群纵向研究
该研究基于苏格兰全国儿童炎症性肠病(PIBD)前瞻性队列,纳入2015年1月1日至2019年6月30日4.5年间诊断的18岁以下患者,回顾性审计生物制剂使用。结果显示PIBD患病数从554例增至644例,新启动生物制剂治疗495次(403例患者),英夫利西单抗占比从87%降至54%,阿达木单抗、维得利珠单抗和乌司奴单抗占比上升,生物类似药渗透率从3%升至91%。
要点
- 苏格兰PIBD患病数从554例增至644例,生物制剂点患病率从20.2%升至43.5%。
- 新启动生物制剂中英夫利西单抗占60%、阿达木单抗32%、维得利珠单抗5%、乌司奴单抗3%。
- 英夫利西单抗启动比例从87%降至54%,阿达木单抗从13%升至31%。
核心结论
- 苏格兰全国儿童服务中生物制剂使用完全统计显示PIBD生物制剂格局快速变化且不可阻挡地增长。
研究设计与样本
- 全国性队列研究,前瞻性识别4.5年期间(2015年1月1日至2019年6月30日)诊断的18岁以下PIBD患者(A1表型,诊断年龄<17岁),回顾性审计接受英夫利西单抗、阿达木单抗、维得利珠单抗或乌司奴单抗治疗和/或首次给药的患者。
主要发现
- 苏格兰PIBD患病病例在研究期间从554例增至644例。
- 共403例PIBD患者启动495次新生物制剂治疗:英夫利西单抗295次(60%)、阿达木单抗161次(32%)、维得利珠单抗24次(5%)、乌司奴单抗15次(3%)。
- 新启动生物制剂比例变化:英夫利西单抗从87%降至54%,阿达木单抗从13%升至31%,维得利珠单抗从0%升至9%,乌司奴单抗从0%升至6%。
- 发病率(首次新生物制剂剂量,不包括生物类似药转换)从6.9%升至8.1%,点患病率(任何生物制剂使用)从20.2%升至43.5%,年均增长20%。
- 新启动抗TNFα药物的生物类似药渗透率从3%升至91%;接受维得利珠单抗和乌司奴单抗的患者人口学特征和结局相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of biologics in paediatric-onset inflammatory bowel disease (PIBD) is rapidly changing. AIMS: To identify the incidence and prevalence of biologic use within Scottish PIBD services, and to describe patient demographics and outcomes for those patients who required escalation of therapy beyond anti-tumour necrosis factor alpha (anti-TNFα) agents METHODS: We captured a nationwide cohort of prospectively identified patients less than 18 years of age with PIBD (A1 phenotype; diagnosed <17 years of age) within paediatric services over a 4.5-year period (1 January 2015-30 June 2019). All patients who received infliximab, adalimumab, vedolizumab or ustekinumab during the study period and/or received their first dose of these biologics were audited retrospectively. RESULTS: Scotland-wide PIBD-prevalence cases increased from 554 to 644 over the study period. A total of 495 incident new-start biological therapies were commenced on 403 PIBD patients: 295 infliximab (60%), 161 adalimumab (32%), 24 vedolizumab (5%) and 15 ustekunumab (3%). The proportion of new-start biologics changed with infliximab initiation rates decreasing (87%-54%) while adalimumab (13%-31%), vedolizumab (0%-9%) and ustekinumab (0%-6%) all increased. The incidence rate (first dose of new biologic not including biosimilar switch) increased from 6.9% to 8.1% over the study period and point prevalence rates (any biologic use) increased from 20.2% to 43.5% - an average annual percentage increase of 20%. Biosimilar penetration of new-start anti-TNFα agents increased from 3% to 91%. Demographics and outcomes of those patients receiving vedolizumab and ustekinumab were similar. CONCLUSIONS: Complete accrual of Scottish nationwide biologic usage within paediatric services demonstrates a rapidly changing, inexorably increasing PIBD biologics landscape.
引用
- Burgess CJ, Jackson R, Chalmers I, et al. The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study. Aliment Pharmacol Ther. 2022. PMID: 36196524. doi:10.1111/apt.17217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。